How should we support pharmaceutical innovation?
Download full text from publisher
References listed on IDEAS
- Adam B. Jaffe & Josh Lerner, 2006. "Innovation and its Discontents," NBER Chapters,in: Innovation Policy and the Economy, Volume 6, pages 27-66 National Bureau of Economic Research, Inc.
- Rexford E. Santerre & John A. Vernon & Carmelo Giaccotto, 2006. "The Impact of Indirect Government Controls on U.S. Drug Prices and R&D," Cato Journal, Cato Journal, Cato Institute, vol. 26(1), pages 143-158, Winter.
- Kremer, Michael R., 1998. "Patent Buyouts: A Mechanism for Encouraging Innovation," Scholarly Articles 3693705, Harvard University Department of Economics.
- Michael Kremer, 1998. "Patent Buyouts: A Mechanism for Encouraging Innovation," The Quarterly Journal of Economics, Oxford University Press, vol. 113(4), pages 1137-1167.
- Boldrin,Michele & Levine,David K., 2010.
"Against Intellectual Monopoly,"
Cambridge University Press, number 9780521127264.
- Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc.
- Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall.
- Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
- Dean Baker, 2008. "The Benefits and Savings of Publicly-Funded Clinical Trials of Prescription Drugs," CEPR Reports and Issue Briefs 2008-09, Center for Economic and Policy Research (CEPR).
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
CitationsCitations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
- Sonia Bhalotra & Atheendar Venkataramani, 2011.
"The Captain of the Men of Death and His Shadow: Long-Run Impacts of Early Life Pneumonia Exposure,"
The Centre for Market and Public Organisation
11/273, Department of Economics, University of Bristol, UK.
- Sonia Bhalotra & Atheendar Venkataramani, 2011. "The Captain of the Men of Death and His Shadow: Long-Run Impacts of Early Life Pneumonia Exposure," CHILD Working Papers wp20_11, CHILD - Centre for Household, Income, Labour and Demographic economics - ITALY.
- Bhalotra, Sonia R. & Venkataramani, Atheendar, 2011. "The Captain of the Men of Death and His Shadow: Long-Run Impacts of Early Life Pneumonia Exposure," IZA Discussion Papers 6041, Institute for the Study of Labor (IZA).
More about this item
KeywordsPharmaceuticals; R&D; patents; prizes; innovation;
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- O34 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Intellectual Property and Intellectual Capital
NEP fieldsThis paper has been announced in the following NEP Reports:
- NEP-ALL-2009-05-23 (All new papers)
- NEP-INO-2009-05-23 (Innovation)
- NEP-IPR-2009-05-23 (Intellectual Property Rights)
- NEP-KNM-2009-05-23 (Knowledge Management & Knowledge Economy)
- NEP-MIC-2009-05-23 (Microeconomics)
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:mcm:sedapp:246. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (). General contact details of provider: http://edirc.repec.org/data/demcmca.html .